|Bid||75.66 x 900|
|Ask||76.43 x 1100|
|Day's Range||74.91 - 76.68|
|52 Week Range||50.50 - 100.00|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||268.31|
|Earnings Date||Mar 07, 2022 - Mar 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||102.50|
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Joining me on today's call are Bill Hoffman, president and chief executive officer; Drew Hykes, chief operating officer; and Mitch Hill, chief financial officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 17.39% and 5.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?